Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study

Published 2016 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma – The SHELTER study
Authors
Keywords
Histone deacetylase inhibitor, Cancer epigenetics, Epigenetic treatment, Drug resistance, Zinc finger protein 64
Journal
JOURNAL OF HEPATOLOGY
Volume 65, Issue 2, Pages 280-288
Publisher
Elsevier BV
Online
2016-03-06
DOI
10.1016/j.jhep.2016.02.043

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.